Literature DB >> 23644969

Successful use of thalidomide for refractory esophageal Crohn's disease.

Jodie A Barkin, Wayne B Schonfeld, Amar R Deshpande.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23644969     DOI: 10.1038/ajg.2013.49

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  6 in total

1.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

2.  Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.

Authors:  Ting Liu; Feng Guo; Xiaomin Zhu; Xiangge He; Lin Xie
Journal:  Exp Ther Med       Date:  2017-09-27       Impact factor: 2.447

3.  The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage.

Authors:  Tasaduq H Wani; Anindita Chakrabarty; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich; Goutam Chowdhury
Journal:  Chem Res Toxicol       Date:  2017-08-02       Impact factor: 3.739

4.  Ustekinumab for Successful Treatment of Refractory Esophageal Crohn's Disease.

Authors:  Jodie A Barkin; Amar R Deshpande
Journal:  ACG Case Rep J       Date:  2016-01-20

5.  Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review.

Authors:  Huiqin Hu; Xinying Wang; Side Liu
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

6.  Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn's disease: a case report.

Authors:  Sunina Nathoo; William A Hood; Sara Keihanian; Amy L Collinsworth; Sarah C Glover
Journal:  J Med Case Rep       Date:  2016-09-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.